NCT01450306

Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Hartford Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The aim of the present study is to determine whether people receiving d-cycloserine and exposure therapy show different brain reactions to symptom provocation compared to people receiving placebo and exposure therapy.

Detailed description

D-cycloserine (DCS) is a partial N-methyl-D-aspartate (NMDA) receptor agonist that may improve or accelerate extinction learning. We will randomly assign people with snake phobia to receive DCS or placebo, and then provide all participants with exposure therapy. We will examine whether people receiving DCS and vs. placebo show different brain reactions to symptom provocation before and after exposure therapy.

Conditions

• Specific Phobia

Interventions

Type	Name	Description
DRUG	D-cycloserine	50 mg d-cycloserine, oral, 1 dose
BEHAVIORAL	Exposure therapy	Single session graded in vivo exposure therapy, 60-180 minutes
DRUG	Placebo	Single capsule of oral placebo, administered once 1 hr prior to exposure therapy

Timeline

• Start date: 2010-07-01
• Primary completion: 2011-12-01
• Completion: 2011-12-01
• First posted: 2011-10-12
• Last updated: 2024-03-15
• Results posted: 2016-04-21

Locations

1 site across 1 country: United States